• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Structural mechanism for PPARalpha regulation by endogenous amino acids

Research Project

Project/Area Number 19K16359
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
Research InstitutionShowa Pharmaceutical University

Principal Investigator

Kamata Shotaro  昭和薬科大学, 薬学部, 助教 (10823932)

Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
KeywordsX線結晶構造解析 / PPAR / アミノ酸
Outline of Research at the Start

核内受容体PPARαは、脂質代謝、糖代謝、アミノ酸代謝、炎症、細胞増殖などの多くの機能を制御している。PPARαアゴニストはフィブラート系薬であり、高脂血症の治療薬として使われるだけでなく、NASHの治療薬としても注目されている。本研究では内在性アミノ酸等とPPARαの複合体結晶のX線結晶構造解析、PPARαアミノ酸点変異体のCoactivatorリクルート能測定、円偏光二色性分析などにより、PPARαの機能制御機構を明らかにする。

Outline of Final Research Achievements

The nuclear receptor PPARa regulates lipid metabolism and induces genes involved in fatty acid beta-oxidation and lipid transport. In this study, we aimed to clarify how endogenous amino acids inhibit PPARa by X-ray crystallography. We examined various conditions, such as delipidating of PPARa and adding a corepressor peptide could not confirm the binding of the target molecule even if crystals were formed. This study established the method for crystallization of various strong and weak PPARa ligands. These techniques have made it possible to obtain PPARa ligand complex structures with high resolution easily. In addition, the PPARa activity and binding sites are different between pemafibrate and other fibrates. PPARs are currently attracting attention as a therapeutic target for NASH, and we obtained both complex structures with saroglitazar, a PPARa/g dual agonist. These results will contribute to developing new PPAR therapeutics for NASH and other diseases.

Academic Significance and Societal Importance of the Research Achievements

本研究によりPPARaの強弱様々なリガンドの結晶化法を確立した。これにより取得の難しかったPPARaリガンド複合体構造を高分解能で容易に得られるようになった。また、フィブラート系薬でも近年認可されたPemafibrateとそれ以外ではPPARa活性と結合部位ともに異なっており、今回得られた構造と治療効果や副作用に関連があるか今後確認する必要がある。現在、PPARはNASHの治療ターゲットとして注目されており、PPARa/g デュアルアゴニストのSaroglitazarについては両方の複合体構造を取得した。これらの結果はNASHを始めとする新たなPPAR治療薬の創出に貢献する。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (12 results)

All 2022 2021 2020 2019

All Journal Article (7 results) (of which Peer Reviewed: 7 results,  Open Access: 4 results) Presentation (5 results)

  • [Journal Article] PPARα-Ligand Binding Modes Revealed by X-ray Crystallography2021

    • Author(s)
      Kamata Shotaro、Ishii Isao
    • Journal Title

      YAKUGAKU ZASSHI

      Volume: 141 Issue: 11 Pages: 1267-1274

    • DOI

      10.1248/yakushi.21-00138

    • NAID

      130008109792

    • ISSN
      0031-6903, 1347-5231
    • Year and Date
      2021-11-01
    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method2021

    • Author(s)
      Oyama Takuji、Kamata Shotaro、Ishii Isao、Miyachi Hiroyuki
    • Journal Title

      Biological and Pharmaceutical Bulletin

      Volume: 44 Issue: 9 Pages: 1202-1209

    • DOI

      10.1248/bpb.b21-00220

    • NAID

      130008082324

    • ISSN
      0918-6158, 1347-5215
    • Year and Date
      2021-09-01
    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist2021

    • Author(s)
      Honda Akihiro、Kamata Shotaro、Satta Chihiro、Machida Yui、Uchii Kie、Terasawa Kazuki、Nemoto Ayane、Oyama Takuji、Ishii Isao
    • Journal Title

      Biological and Pharmaceutical Bulletin

      Volume: 44 Issue: 9 Pages: 1210-1219

    • DOI

      10.1248/bpb.b21-00232

    • NAID

      130008082321

    • ISSN
      0918-6158, 1347-5215
    • Year and Date
      2021-09-01
    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography2021

    • Author(s)
      Kamata Shotaro、Oyama Takuji、Ishii Isao
    • Journal Title

      STAR Protocols

      Volume: 2 Issue: 1 Pages: 100364-100364

    • DOI

      10.1016/j.xpro.2021.100364

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates2020

    • Author(s)
      Kamata Shotaro、Oyama Takuji、Saito Kenta、Honda Akihiro、Yamamoto Yume、Suda Keisuke、Ishikawa Ryo、Itoh Toshimasa、Watanabe Yasuo、Shibata Takahiro、Uchida Koji、Suematsu Makoto、Ishii Isao
    • Journal Title

      iScience

      Volume: 23 Issue: 11 Pages: 101727-101727

    • DOI

      10.1016/j.isci.2020.101727

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Abnormal Amino Acid Profiles of Blood and Cerebrospinal Fluid from Cystathionine β-Synthase-Deficient Mice, an Animal Model of Homocystinuria2019

    • Author(s)
      Akahoshi N, Yokoyama A, Nagata T, Miura A, Kamata S, Ishii I.
    • Journal Title

      Biological and Pharmaceutical Bulletin

      Volume: 42 Issue: 6 Pages: 1054-1057

    • DOI

      10.1248/bpb.b19-00127

    • NAID

      130007657698

    • ISSN
      0918-6158, 1347-5215
    • Year and Date
      2019-06-01
    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Preeclampsia-Like Features and Partial Lactation Failure in Mice Lacking Cystathionine γ-Lyase-An Animal Model of Cystathioninuria.2019

    • Author(s)
      Akahoshi N, Handa H, Takemoto R, Kamata S, Yoshida M, Onaka T, Ishii I.
    • Journal Title

      Int J Mol Sci.

      Volume: 20 Issue: 14 Pages: 3507-3507

    • DOI

      10.3390/ijms20143507

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] X線結晶構造解析による3種フィブラート系薬のPPARα/δ/γリガンド結合部位それぞれへの結合様式の比較2022

    • Author(s)
      鎌田 祥太郎, 本多 彰宏, 町田優衣, 内井希恵, 椎山結 増田莉紗, 垣生有希, 柏木野花, 大山 拓次, 石井 功
    • Organizer
      日本薬学会第142年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] X線結晶構造解析により得られたPPARαリガンド結合部位と内在性脂肪酸及びフィブラート系薬の複合体構造2021

    • Author(s)
      鎌田 祥太郎, 大山 拓次, 齊藤健太, 本多 彰宏, 山本 ゆめ, 須田 圭介, 石川 諒, 石井 功
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] NAFLD治験薬かつ糖尿病性脂質異常症治療薬SaroglitazarのPPARα/γ dualアゴニストとしての構造基盤2021

    • Author(s)
      本多 彰宏, 颯田 千尋, 町田 優衣, 内井 希恵, 寺沢 和樹, 根本 彩音, 鎌田 祥太郎, 大山 拓次, 石井 功
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Annual Research Report
  • [Presentation] NASH治験薬Lanifibranor-ヒトPPARγ複合体結晶のX線構造解析2021

    • Author(s)
      町田 優衣, 内井 希恵, 増田 莉紗, 椎山 結, 本多 彰宏, 鎌田 祥太郎, 石井 功
    • Organizer
      2021年度生化学会関東支部例会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 核内受容体PPAR alphaのCD測定法による熱安定性評価2019

    • Author(s)
      石川諒, 本多彰宏, 鎌田祥太郎, 石井功
    • Organizer
      第5回 次世代を担う若手のためのレギュラトリーサイエンスフォーラム
    • Related Report
      2019 Research-status Report

URL: 

Published: 2019-04-18   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi